CHAUHAN, SUBHASH C.

Professor
Pharmaceutical Sciences

Office: 224 Cancer Research Building
Tel: (901) 448-2175
schauha1@uthsc.edu

Education

  • Ph.D., Central Drug Research Institute, Lucknow, India (BRA University, Agra), Reproductive Endocrinology

Research Description

Subhash Chauhan Lab

Research Interest: Developing Molecular Markers for Early Cancer Diagnosis and Targeted Therapy for Cancer Treatment

Biomarkers for Early Cancer Diagnosis: Primary research interest of Dr. Chauhan’s lab is to identify and characterize the diagnostic and therapeutic targets for cancer. Main focus of our research group is to elucidate the regulatory mechanisms of cell-cell adhesion and anti-adhesion molecules that cause cancers. This research is aimed for the identification and characterization of biomarkers that aberrantly express or localize in cancer cells in order to develop newer tools for early disease diagnosis. We are utilizing genomics and proteomics approach for identification of novel early diagnostic markers. Recently we have identified a novel trans-membrane mucin MUC13 which is highly over-expressed ovarian and pancreatic and colon cancer cells. This may be potential biomarker for early cancer diagnosis as well as a good target for antibody guided targeted cancer therapy.

Optimization of Radioimmunotherapy for Cancer Treatment: The other research interest of Dr. Chauhan’s lab is to develop novel radioimmunotherapy (RIT) and radioimmunodiagnostic (RID) modalities for the treatment and diagnosis of gynecological malignancies. Monoclonal antibodies/engineered single-chain Fvs offer a powerful approach to cancer therapy in view of their exquisite specificity and targeting capability via the delivery of cytocidal agents (i.e. radionuclides, enzymes, genes, drugs and cytotoxins). This research project is aimed to develop novel genetically engineered antibody molecules with reduced immunogenicity, desirable size and altered pharmacokinetics for the RID/RIT applications.

Development of a Novel Nanotechnology Based Therapy: Nonspecific distribution and suboptimal delivery of the anti-cancer drug(s) to the tumor cells are the major hindrances in the successful use of traditional chemotherapy. The cancer tissues overexpress TAG-72, MUC1, MUC13 and MUC16 antigens, and a combination of the antibodies against these three antigens will potentially recognize 100% of the cancer cells. These antibodies can be used to deliver the radionuclides and nanoparticles-encapsulated drugs specifically to the cancer cells. In addition, antibodies that have been labeled with alpha and beta emitting radionuclides (211At, 177Lu and 131I) of different linear energy transfer (LET) and have been designed against these tumor antigens will effectively target various sizes of metastatic lesions. Additionally, we are also developing a novel nanotechnology based gene therapy for cancer.

Lab Member Tab Page:

Sheema Khan, PhD, Postdoctoral Fellow; Rishi K. Gara, PhD; Postdoctoral Fellow;

Saif Zaman, PhD, Postdoctoral Fellow, MD Sikander, PhD, Postdoctoral Fellow

Neeraj Chauhan, Graduate Student; Aditya Ganju, Graduate Student

Vaibhav Gandhi, Graduate Student, Saini Setua, Graduate Student

Sonam Kumari, Graduate Student

 

Information for the Lay Person:

Primary research interest of Dr. Chauhan’s lab is to identify and characterize the diagnostic and therapeutic targets for cancer, such as ovarian cancer, cervical cancer, prostate cancer, pancreatic cancer. This research is aimed for the identification and characterization of biomarkers that aberrantly express or localize in cancer cells in order to develop newer tools for early disease diagnosis. Recently we have identified a novel trans-membrane mucin MUC13 which is highly over-expressed ovarian and pancreatic cancer cells. This may be potential biomarker for early cancer diagnosis as well as a good target for antibody guided targeted cancer therapy.

Press Releases:

Curcumin nanoparticles the key to resistant cancers

Pre-treatment with curcumin, a component of the spice turmeric, makes ovarian cancer cells more vulnerable to chemo- and radio-therapy. Researchers writing in BioMed Central’s open access Journal of Ovarian Research found that delivering the curcumin via very small (less than 100nm) nanoparticles enhanced the sensitizing effect.

Subhash Chauhan, PhD and Meena Jaggi, PhD led a team of researchers from the Sanford Research/USD and University of South Dakota, USA, carried out the in vitro study. They said, “One strategy to improve the effectiveness and limit the toxicity of cancer therapy is to induce chemo/radio-sensitization in cancer cells using natural dietary phytochemicals like curcumin. However, curcumin is poorly absorbed by the body, which limits its effectiveness; therefore, we have developed a nanoparticle formulation, Nano-CUR, to provide increased bioavailability as well as targeted delivery of curcumin into tumors”.

The researchers tested the effects of their curcumin formulation on therapy-resistant ovarian cancer cells. They were able to show, for the first time, that the pre-treatment lowers the dose of cisplatin and radiation treatment needed to suppress the growth of the cancer cells. According to Chauhan, “Nanoparticle mediated curcumin delivery will further improve the sensitization and therapeutic capabilities. This study demonstrates a novel pre-treatment strategy that could be implemented in pre-clinical animal models and in future clinical trials”.

Research Keywords

Mucins, MUC13, Cancer Research, Targeted Therapies, miRNA, siRNA, Curcumin, Nanoparticle Technology, Antibody/Aptamer, Radionuclides   

Research Interest/Specialty

Cancer Research, Molecular Cancer Therapeutics, Targeted Therapies, Tumor Progression and Metastasis, Antibody Therapies and Nanotechnology

Publications

  1. Yallapu, MM, Katti, KS, Katti, DR, Mishra, SR, Khan, S, Jaggi, M, Chauhan, SC. The roles of cellular nanomechanics in cancer. Med Res Rev, 35 (1), 198-223, 2015.
  2. Maher, DM, Khan, S, Nordquist, JL, Ebeling, MC, Bauer, NA, Kopel, L, Singh, MM, Halaweish, F, Bell, MC, Jaggi, M, Chauhan, SC. Ormeloxifene efficiently inhibits ovarian cancer growth. Cancer Lett, 356 (2 Pt B), 606-12, 2015.
  3. Yallapu, MM, Khan, S, Maher, DM, Ebeling, MC, Sundram, V, Chauhan, N, Ganju, A, Balakrishna, S, Gupta, BK, Zafar, N, Jaggi, M, Chauhan, SC. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials, 35 (30), 8635-48, 2014.
  4. Gara, RK, Kumari, S, Ganju, A, Yallapu, MM, Jaggi, M, Chauhan, SC. Slit/Robo pathway: a promising therapeutic target for cancer. Drug Discov Today, 2014.
  5. Khan, S, Ebeling, MC, Zaman, MS, Sikander, M, Yallapu, MM, Chauhan, N, Yacoubian, AM, Behrman, SW, Zafar, N, Kumar, D, Thompson, PA, Jaggi, M, Chauhan, SC. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Oncotarget, 5 (17), 7599-609, 2014.
  6. Sundram, V, Ganju, A, Hughes, JE, Khan, S, Chauhan, SC, Jaggi, M. Protein kinase D1 attenuates tumorigenesis in colon cancer by modulating β-catenin/T cell factor activity. Oncotarget, 5 (16), 6867-84, 2014.
  7. Ganju, A, Yallapu, MM, Khan, S, Behrman, SW, Chauhan, SC, Jaggi, M. Nanoways to overcome docetaxel resistance in prostate cancer. Drug Resist Updat, 2014.
  8. Srivastava, A, Goldberger, H, Dimtchev, A, Ramalinga, M, Chijioke, J, Marian, C, Oermann, EK, Uhm, S, Kim, JS, Chen, LN, Li, X, Berry, DL, Kallakury, BV, Chauhan, SC, Collins, SP, Suy, S, Kumar, D. MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214. PLoS One, 8 (10), e76994, 2013.
  9. Khan, S, Ansarullah, , Kumar, D, Jaggi, M, Chauhan, SC. Targeting microRNAs in pancreatic cancer: microplayers in the big game. Cancer Res, 73 (22), 6541-7, 2013.
  10. Gupta, BK, Maher, DM, Ebeling, MC, Stephenson, PD, Puumala, SE, Koch, MR, Aburatani, H, Jaggi, M, Chauhan, SC. Functions and regulation of MUC13 mucin in colon cancer cells. J Gastroenterol, 2013.
  11. Sane, S, Abdullah, A, Boudreau, DA, Autenried, RK, Gupta, BK, Wang, X, Wang, H, Schlenker, EH, Zhang, D, Telleria, C, Huang, L, Chauhan, SC, Rezvani, K. Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells. Cell Death Dis, 5, e1118, 2013.
  12. Yallapu, MM, Ebeling, MC, Khan, S, Sundram, V, Chauhan, N, Gupta, BK, Puumala, SE, Jaggi, M, Chauhan, SC. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Mol Cancer Ther, 12 (8), 1471-80, 2013.
  13. Yallapu, MM, Ebeling, MC, Jaggi, M, Chauhan, SC. Plasma proteins interaction with curcumin nanoparticles: implications in cancer therapeutics. Curr Drug Metab, 14 (4), 504-15, 2013.
  14. Gara, RK, Sundram, V, Chauhan, SC, Jaggi, M. Anti-cancer potential of a novel SERM ormeloxifene. Curr Med Chem, 20 (33), 4177-84, 2013.
  15. Gupta, BK, Maher, DM, Ebeling, MC, Sundram, V, Koch, MD, Lynch, DW, Bohlmeyer, T, Watanabe, A, Aburatani, H, Puumala, SE, Jaggi, M, Chauhan, SC. Increased expression and aberrant localization of mucin 13 in metastatic colon cancer. J Histochem Cytochem, 60 (11), 822-31, 2012.
  16. Zaman, MS, Maher, DM, Khan, S, Jaggi, M, Chauhan, SC. Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Res, 5 (1), 44, 2012.
  17. Yallapu, MM, Jaggi, M, Chauhan, SC. Curcumin nanomedicine: a road to cancer therapeutics. Curr Pharm Des, 19 (11), 1994-2010, 2012.
  18. Yallapu, MM, Othman, SF, Curtis, ET, Bauer, NA, Chauhan, N, Kumar, D, Jaggi, M, Chauhan, SC. Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. Int J Nanomedicine, 7, 1761-79, 2012.
  19. Patacsil, D, Osayi, S, Tran, AT, Saenz, F, Yimer, L, Shajahan, AN, Gokhale, PC, Verma, M, Clarke, R, Chauhan, SC, Kumar, D. Vitamin E succinate inhibits survivin and induces apoptosis in pancreatic cancer cells. Genes Nutr, 7 (1), 83-9, 2012.
  20. Yallapu, MM, Jaggi, M, Chauhan, SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today, 17 (1-2), 71-80, 2012.
  21. Chauhan, SC, Ebeling, MC, Maher, DM, Koch, MD, Watanabe, A, Aburatani, H, Lio, Y, Jaggi, M. MUC13 mucin augments pancreatic tumorigenesis. Mol Cancer Ther, 11 (1), 24-33, 2012.
  22. Yallapu, MM, Dobberpuhl, MR, Maher, DM, Jaggi, M, Chauhan, SC. Design of curcumin loaded cellulose nanoparticles for prostate cancer. Curr Drug Metab, 13 (1), 120-8, 2012.
  23. Yallapu, MM, Ebeling, MC, Chauhan, N, Jaggi, M, Chauhan, SC. Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes. Int J Nanomedicine, 6, 2779-90, 2011.
  24. Sundram, V, Chauhan, SC, Ebeling, M, Jaggi, M. Curcumin attenuates β-catenin signaling in prostate cancer cells through activation of protein kinase D1. PLoS One, 7 (4), e35368, 2011.
  25. Sundram, V, Chauhan, SC, Jaggi, M. Emerging roles of protein kinase D1 in cancer. Mol Cancer Res, 9 (8), 985-96, 2011.
  26. Maher, DM, Gupta, BK, Nagata, S, Jaggi, M, Chauhan, SC. Mucin 13: structure, function, and potential roles in cancer pathogenesis. Mol Cancer Res, 9 (5), 531-7, 2011.
  27. Schmidt-Grimminger, DC, Bell, MC, Muller, CJ, Maher, DM, Chauhan, SC, Buchwald, DS. HPV infection among rural American Indian women and urban white women in South Dakota: an HPV prevalence study. BMC Infect Dis, 11, 252, 2011.
  28. Yellepeddi, VK, Kumar, A, Maher, DM, Chauhan, SC, Vangara, KK, Palakurthi, S. Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT. Anticancer Res, 31 (3), 897-906, 2011.